Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Carl Sailer is Director at Acurx Pharmaceuticals. OQRO lists 2 transactions filed with the SEC under this name, the latest on Apr 22, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
Acurx PharmaceuticalsACXP
2 disclosures · Jan 2025 – Apr 2026 · 1 bought
Apr 20, 20262,150disclosed Apr 22
DetailsOfficial recordJan 6, 2025Bought~$25Kdisclosed Jan 8
DetailsOfficial recordAs of the latest filing on , Carl Sailer reported holding 137,183 shares of Acurx Pharmaceuticals (ACXP), worth about $132K at the last close of $1 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Acurx Pharmaceuticals ACXP | 137,183 | 137K direct | $1 | $132K | Jan 6, 2025 |
Is this Carl Sailer’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Jan 6, 2025, Carl Sailer reported holding 137,183 shares of Acurx Pharmaceuticals (ACXP). At the last close of $1 on Nov 13, 2026, that is about $132K. This is the stake disclosed in filings, not a net worth.
Carl Sailer bought shares on the open market in 2021, 2022 and 2025.
In SEC filings since 2021: the latest open-market purchase is from 2025; no open-market sale is on record.
Acurx Pharmaceuticals (ACXP), from 2021 to 2025: 4 purchases and 0 sales.
Carl Sailer bought shares on the open market in 2021, 2022 and 2025.
Carl Sailer reported 4 open-market purchases and 0 sales since 2021; purchases in 3 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $25K1×1 trade | — |
| 2022 | $75K1×1 trade | — |
| 2021 | $100K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Carl Sailer reported 4 open-market purchases and 0 sales here, 2021 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
